Life Science REIT plc

BATS-CHIXE:LABSL Stock Report

Market Cap: UK£134.4m

Life Science REIT Valuation

Is LABSL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LABSL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: LABSL (£0.38) is trading above our estimate of fair value (£0.09)

Significantly Below Fair Value: LABSL is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LABSL?

Key metric: As LABSL is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for LABSL. This is calculated by dividing LABSL's market cap by their current revenue.
What is LABSL's PS Ratio?
PS Ratio6.7x
SalesUK£20.12m
Market CapUK£134.40m

Price to Sales Ratio vs Peers

How does LABSL's PS Ratio compare to its peers?

The above table shows the PS ratio for LABSL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.2x
CRT Care REIT
6.5x6.0%UK£346.0m
THRL Target Healthcare REIT
7.6x3.2%UK£527.8m
AGR Assura
7.8x4.8%UK£1.3b
PHP Primary Health Properties
7.2x-0.4%UK£1.3b
LABSL Life Science REIT
6.7x6.3%UK£134.4m

Price-To-Sales vs Peers: LABSL is good value based on its Price-To-Sales Ratio (6.7x) compared to the peer average (7.2x).

Price to Sales Ratio vs Industry

How does LABSL's PS Ratio compare vs other companies in the Global Health Care REITs Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
No. of Companies6PS03.26.49.612.816+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: LABSL is expensive based on its Price-To-Sales Ratio (6.7x) compared to the Global Health Care REITs industry average (6.5x).

Price to Sales Ratio vs Fair Ratio

What is LABSL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LABSL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6.7x
Fair PS Ratio4.4x

Price-To-Sales vs Fair Ratio: LABSL is expensive based on its Price-To-Sales Ratio (6.7x) compared to the estimated Fair Price-To-Sales Ratio (4.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst LABSL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUK£0.38
UK£0.52
+37.0%
16.8%UK£0.60UK£0.40n/a3
Nov ’25UK£0.42
UK£0.58
+35.7%
31.2%UK£0.80UK£0.36n/a3
Oct ’25UK£0.40
UK£0.58
+45.8%
31.2%UK£0.80UK£0.36n/a3
Sep ’25UK£0.34
UK£0.58
+71.1%
31.2%UK£0.80UK£0.36n/a3
Aug ’25UK£0.34
UK£0.61
+78.4%
23.9%UK£0.80UK£0.45n/a3
Jul ’25UK£0.34
UK£0.61
+79.8%
23.9%UK£0.80UK£0.45n/a3
Jun ’25UK£0.33
UK£0.61
+81.6%
23.9%UK£0.80UK£0.45n/a3
May ’25UK£0.40
UK£0.61
+52.0%
23.9%UK£0.80UK£0.45n/a3
Apr ’25UK£0.40
UK£0.61
+53.6%
23.9%UK£0.80UK£0.45n/a3
Mar ’25UK£0.44
UK£0.83
+88.6%
6.0%UK£0.90UK£0.79n/a3
Feb ’25UK£0.57
UK£0.83
+45.6%
6.0%UK£0.90UK£0.79n/a3
Jan ’25UK£0.63
UK£0.85
+34.7%
5.3%UK£0.90UK£0.79n/a3
Dec ’24UK£0.63
UK£0.85
+35.4%
5.3%UK£0.90UK£0.79n/a3
Nov ’24UK£0.61
UK£0.88
+43.8%
2.3%UK£0.90UK£0.86UK£0.422
Oct ’24UK£0.70
UK£0.88
+26.1%
2.3%UK£0.90UK£0.86UK£0.402
Sep ’24UK£0.64
UK£0.88
+36.6%
2.3%UK£0.90UK£0.86UK£0.342
Aug ’24UK£0.63
UK£0.88
+39.7%
2.3%UK£0.90UK£0.86UK£0.342
Jul ’24UK£0.68
UK£0.88
+29.4%
2.3%UK£0.90UK£0.86UK£0.342
Jun ’24UK£0.74
UK£1.00
+35.1%
14.0%UK£1.14UK£0.86UK£0.332
May ’24UK£0.68
UK£1.00
+46.2%
14.0%UK£1.14UK£0.86UK£0.402

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Xior Student Housing

€1.3b

Xior Student Housing NV is the first Belgian public regulated real estate company (RREC) specialising in the student housing segment in Belgium, the Netherlands, Spain, Portugal, Germany, Poland, Denmark and Sweden.

0RD8

€30.40

7D

1.7%

1Y

-3.0%

Montea Comm. VA

€1.5b

Montea NV is a public regulated real estate company under Belgian law (GVV/SIR) that specializes in logistics real estate in Belgium, the Netherlands, France, and Germany.

0LBY

€66.50

7D

4.3%

1Y

-13.8%

Care Property Invest

€455.7m

Care Property Invest NV/SA is a Public Regulated Real Estate Company (public RREC) under Belgian law.

0R6H

€12.32

7D

2.0%

1Y

-3.9%